Stelara
Amgen’s Wezlana Emerges as Competitor to J&J’s Stelara, Shaping Medicare Negotiations
Johnson & Johnson may find a silver lining in the recent FDA approval of Amgen’s biosimilar for Stelara. This approval ...
Amgen Secures FDA Approval for Stelara Biosimilar, Awaits 2025 Launch Post-Settlement
The FDA has granted approval to Amgen for its biosimilar rendition of Johnson & Johnson’s renowned autoimmune medication, Stelara. However, ...
J&J confident in new products as Stelara faces biosimilar threat
In the third quarter of 2023, Johnson & Johnson (J&J) exceeded analyst expectations, solidifying its position as a pharma and ...
AbbVieâs Skyrizi beats J&Jâs Stelara in head-to-head Crohnâs disease trial
AbbVie’s Skyrizi has notched a resounding victory over Johnson & Johnson’s biologic drug Stelara in treating Crohn’s disease, as revealed ...
Teva and Alvotech face FDA rejection for Stelara biosimilar after Humira setbacks
Ongoing issues at the Alvotech manufacturing facility in Reykjavik have led to yet another FDA rejection, this time affecting the ...
AbbVieâs Skyrizi beats J&Jâs Stelara in Crohnâs disease showdown
AbbVie’s revolutionary anti-inflammatory medication, Skyrizi, has been consistently outperforming its competitors in recent clinical trials, making waves in the field ...
Sandoz to market Samsung Bioepisâ biosimilar of Stelara in US and Canada
Sandoz is expanding its biosimilar portfolio by signing a commercialization agreement with Samsung Bioepis for a biosimilar version of Johnson ...
Another Stelara patent settlement was reached by J&J, this time with Alvotech and Teva
Source – Johnson & Johnson By early 2025, a new settlement may allow for the entry of a second biosimilar ...
